These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 18985968)

  • 21. Medicare program; rural health clinics: amendments to participation requirements and payment provisions; and establishment of a quality assessment and performance improvement program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(247):74791-818. PubMed ID: 14976981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2015 Jul; 80(130):38915-40. PubMed ID: 26155603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prescription drug products; patient package insert requirements--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(1):28-30. PubMed ID: 10324121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The final sampling regulations of the Prescription Drug Marketing Act are alive and well: is your sampling program compliant?
    Romanski JA
    Food Drug Law J; 2003; 58(4):649-60. PubMed ID: 15027455
    [No Abstract]   [Full Text] [Related]  

  • 25. Biological products; blood specificity designators; technical amendments--FDA. Final rule; technical amendments.
    Fed Regist; 1994 May; 59(87):23636-7. PubMed ID: 10184096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Foreign establishment registration and listing. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Nov; 66(228):59138-61. PubMed ID: 11776289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prescription drug marketing act: a solution in search of a problem?
    Angarola RT; Beach JE
    Food Drug Law J; 1996; 51(1):21-55. PubMed ID: 11794352
    [No Abstract]   [Full Text] [Related]  

  • 28. State certification of mammography facilities. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Feb; 67(25):5446-69. PubMed ID: 11852885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologics products; establishment registration and product listing for manufacturers of human blood and blood products; amendment to exempt certain transfusion services from registration--FDA. Final rule.
    Fed Regist; 1984 Aug; 49(171):34448-51. PubMed ID: 10299643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Supplemental standards of ethical conduct and financial disclosure requirements for employees of the Department of Health and Human Services. Interim final rule with request for comments.
    Department of Health and Human Services (HHS)
    Fed Regist; 2005 Feb; 70(22):5543-65. PubMed ID: 15690579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Revisions to the requirements applicable to blood, blood components, and source plasma. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Direct final rule.
    Fed Regist; 1999 Aug; 64(160):45366-74. PubMed ID: 10558597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigational new drugs: export requirements for unapproved new drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Nov; 70(225):70720-30. PubMed ID: 16304736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toll-free number for reporting adverse events on labeling for human drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Oct; 73(209):63886-97. PubMed ID: 19112682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 35. A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act.
    Lietzan EK
    Food Drug Law J; 2004; 59(2):287-323. PubMed ID: 15298013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug and drug-related supply promotion by pharmaceutical company representatives at VA facilities. Final rule.
    Department of Veterans Affairs
    Fed Regist; 2012 Mar; 77(43):12997-3009. PubMed ID: 22420057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Not as easy as it may appear: using radio frequency identification technology to fulfill the Prescription Drug Marketing Act's elusive pedigree requirement.
    Asamoah AK
    Food Drug Law J; 2006; 61(2):385-418. PubMed ID: 16903035
    [No Abstract]   [Full Text] [Related]  

  • 38. Implementation of the Comprehensive Methamphetamine Control Act of 1996; regulation of pseudoephedrine, phenylpropanolamine, and combination ephedrine drug products and reports of certain transactions to nonregulated persons. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2002 Mar; 67(60):14853-62. PubMed ID: 11922057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1998 MQSA (Mammography Quality Standards Act) final rule released. American College of Radiology.
    Radiol Manage; 1998; 20(4):51-5. PubMed ID: 10181472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Registration requirements for importers and manufacturers of prescription drug products containing ephedrine, pseudoephedrine, or phenylpropanolamine. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2010 Feb; 75(20):4973-82. PubMed ID: 20352663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.